Actively Recruiting
An Integrated Algorithm for Surgical Intervention in Chronic Lymphedema After Breast Cancer Treatment: The Basel Lymphedema Protocol
Led by University Hospital, Basel, Switzerland · Updated on 2025-02-10
500
Participants Needed
1
Research Sites
1095 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Basel, Switzerland
Lead Sponsor
S
Sana Kliniken Düsseldorf GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of the investigators is to develop an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. This will be achieved by retrospectively analysing a subgroup of patients who had breast cancer-related surgery prior to lymphedema.
CONDITIONS
Official Title
An Integrated Algorithm for Surgical Intervention in Chronic Lymphedema After Breast Cancer Treatment: The Basel Lymphedema Protocol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Status post breast cancer or another type of cancer or no cancer
- Chronic lymphedema lasting over three months present before surgical treatment
- Underwent one or more types of surgical procedures for chronic lymphedema treatment
- Surgical procedures used include LNVA, LVA, Tumescent Liposuction, VLNT, and/or Water-Assisted Liposuction
You will not qualify if you...
- Inclusion criteria not met
- Loss to follow-up or data not successfully collected
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
E
Elisabeth A Kappos, PD Dr. med
CONTACT
A
Adriano Fabi, BMed
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here